FibroGen, Inc. (NASDAQ:FGEN) Q2 2020 Earnings Conference Call - Final Transcript
Aug 06, 2020 • 05:00 pm ET
Good afternoon, ladies and gentlemen, and welcome to the FibroGen Second Quarter 2020 Financial Results. [Operator Instructions]
I would now like to hand the conference over to your host, Michael Tung. Please go ahead.
Thank you, Ashley, and good afternoon, everyone. I'm Michael Tung, Vice President of Corporate Strategy and Investor Relations at FibroGen. Joining me on today's call are Enrique Conterno, our Chief Executive Officer; Thane Wettig, our Chief Commercial Officer; Pat Controneo, our Chief Financial Officer; Dr. Peony Yu, our Chief Medical Officer; Chris Chung, our Senior Vice President of China Operations; and Dr. Elias Kouchakji, our Senior Vice President of Clinical Development, Drug Safety and Pharmacovigilance. The format for today's call includes prepared remarks from Enrique and Pat. After which, we will open up the call for Q&A.
I would like to remind you that remarks made on today's call include forward-looking statements about FibroGen. Such statements may include, but are not limited to, our collaborations with AstraZeneca and Astellas; financial guidance; the initiation, enrollment, design, conduct and results of clinical trials; our regulatory strategies and potential regulatory results; our research and development activities; commercial results and results of operations; risks related to our business; and certain other business matters. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. For a more complete description of these and other material risks can be found in FibroGen's filings with the SEC, including its most recent Form 10-K and Form 10-Q. FibroGen does not undertake any obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. The press release reporting our financial results and business update and a webcast of today's conference call can be found on the Investors section of FibroGen's website at www.fibrogen.com.
And with that, I would like to turn the call over to Enrique Conterno, our CEO. Enrique?
Thank you, Mike. Good afternoon, everyone, and welcome to our second quarter 2020 earnings call. Despite the challenges presented by the COVID-19 pandemic, on behalf of FibroGen, I'd like to reassure patients, health care providers, investigators and stakeholders of our continued commitment to bring our potential first-in-class medicines to patients suffering from chronic and life-threatening conditions. We continue to monitor the situation closely. To our employees and our patients and to the health care providers, regulators and countless others who interact with FibroGen, please know our thoughts are you and your families. I want take a moment to welcome both Dr. Aoife Brennan, and Dr. Ben Cravatt to our Board of Directors at this exciting point in Fibrogen's history. Aoife's experience in rare diseases and clinical development and Ben's world-class expertise in biology and chemistry will provide invaluable perspective to our Board.
With today's earnings call, we are implementing a new format with a goal to improving communications with the investment community and other stakeholders. I will begin by providing a high-level summary of the